Back to School: How biopharma can reboot drug development. Access exclusive analysis here

DAC:GLP-1: CJC started a placebo-controlled Dutch Phase I dose-ranging study of DAC:GLP-1 in up to 110 subjects. In the first part of the study, up to 58 volunt

ConjuChem Inc. (TSE:CJC), Montreal, Quebec
Product: DAC:GLP-1 (CJC-1131)
Business: Metabolic
Therapeutic

Read the full 115 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE